Andra AP fonden Purchases 337,100 Shares of Gilead Sciences, Inc. $GILD

Andra AP fonden boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 140.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 577,800 shares of the biopharmaceutical company’s stock after buying an additional 337,100 shares during the period. Gilead Sciences makes up 0.9% of Andra AP fonden’s holdings, making the stock its 13th biggest holding. Andra AP fonden’s holdings in Gilead Sciences were worth $64,061,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Ethos Financial Group LLC bought a new position in shares of Gilead Sciences in the 2nd quarter worth about $306,000. Resona Asset Management Co. Ltd. grew its stake in Gilead Sciences by 1.7% during the second quarter. Resona Asset Management Co. Ltd. now owns 450,144 shares of the biopharmaceutical company’s stock worth $49,894,000 after purchasing an additional 7,426 shares during the period. Atlantic Union Bankshares Corp grew its stake in Gilead Sciences by 4.7% during the second quarter. Atlantic Union Bankshares Corp now owns 183,782 shares of the biopharmaceutical company’s stock worth $20,376,000 after purchasing an additional 8,300 shares during the period. TKG Advisors LLC acquired a new position in Gilead Sciences in the second quarter valued at approximately $5,153,000. Finally, Cherry Creek Investment Advisors Inc. lifted its stake in Gilead Sciences by 9.6% in the second quarter. Cherry Creek Investment Advisors Inc. now owns 7,943 shares of the biopharmaceutical company’s stock valued at $881,000 after buying an additional 693 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 71,500 shares of company stock valued at $8,336,040 over the last 90 days. Insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Gilead Sciences in a research report on Monday. Citigroup raised their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Wednesday, October 8th. Truist Financial reaffirmed a “buy” rating and issued a $145.00 price target (up from $127.00) on shares of Gilead Sciences in a research note on Monday. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, UBS Group raised their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $125.08.

Gilead Sciences Stock Down 0.3%

Shares of NASDAQ GILD opened at $122.58 on Thursday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a 50-day moving average price of $116.15 and a 200-day moving average price of $111.99. The stock has a market capitalization of $152.10 billion, a P/E ratio of 24.42, a P/E/G ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the business posted $2.02 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.